Wenjing Jiang

Dr. Wenjing Jiang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in IEEE Transactions on Neural Systems and Rehabilitation Engineering
Verified
Journal Article
Open access
HTHaoyu Tian
Haoyu Tian
HLHaiyun Li
Haiyun Li
WJWenjing Jiang
Wenjing Jiang
XMXin Ma
Xin Ma
XLXiang Li
Xiang Li
YLYibin Li
Yibin Li
Gait impairment in Parkinson’s Disease (PD) is quantitatively assessed using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), a well-established clinical tool. Objective and efficient PD gait assessment is crucial for developing interventions to slow or halt its advancement. Skeleton-based PD gait MDS-UPDRS score estimation has attracted increasing interest in improving diagnostic efficiency and objectivity. However, previous works ignore the important cross-spacetime dependencies between joints in PD gait. Moreover, existing PD gait skeleton datasets are very small, which is a big issue in deep learning-based gait studies. In this work, we collect a sizable PD gait skeleton dataset by multi-view Azure Kinect sensors. The collected dataset contains 102 PD patients and 30 healthy older adults. In addition, gait data from 16 young adults (aged 24–50 years) are collected to further examine the effect of age on PD gait assessment. For skeleton-based automatic PD gait analysis, we propose a novel cross-spatiotemporal graph convolution network (CST-GCN) to learn complex features of gait patterns. Specifically, a gait graph labeling strategy is designed to assemble and group cross-spacetime neighbors of the root node according to the spatiotemporal semantics of the gait skeleton. Based on this strategy, the CST-GCN module explicitly models the cross-spacetime dependencies among joints. Finally, a dual-path model is presented to realize the modeling and fusion of spatial, temporal, and cross-spacetime gait features. Extensive experiments validate the effectiveness of our method on the collected dataset.

4 May 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAiling Bao
Ailing Bao
WJWenjing Jiang
Wenjing Jiang
XXXiansong Xie
Xiansong Xie
DWDeyuan Wang
Deyuan Wang
ZDZiquan Deng
Ziquan Deng
YYYingkun Yan
Yingkun Yan

9 July 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
JMJun Ma
Jun Ma
AWAijun Wang
Aijun Wang
WJWenjing Jiang
Wenjing Jiang
LMLin Ma
Lin Ma
YLYan Lin
Yan Lin
Background: Paraneoplastic syndrome is a distant effect caused by malignant tumors, which is related to the production of cellular immune response. The nervous system is the most common involved system of paraneoplastic syndrome. It is easy to be misdiagnosed. Lung cancer is the most common cancer relating to paraneoplastic neurological syndrome (PNS).Method: This study retrospectively analyzed clinical data of patients with the combination of PNS and lung cancer between January 2005 and March 2021 at Qilu Hospital of Shandong University, China.Results: A total of 111 patients were diagnosed with lung cancer complicated with PNS. A total of 95 (85.6%) cases had neurological symptoms as the first symptom. Sixty‐three cases had the pathological results. A total of 43 (68.3%) of small cell lung cancer (SCLC) were diagnosed. PNS patients diagnosed with SCLC included peripheral neuropathy (15 cases, 34.9%). PNS patients diagnosed with non‐small cell lung cancer (NSCLC) included peripheral neuropathy (6 cases, 30%) and limbic encephalitis (6 cases, 30%). Anti‐Hu is popular in patients with SCLC (12 cases, 42.9%) and NSCLC (6 cases, 40%).Conclusions: Most patients with PNS had neurological symptoms as the first symptom. It was more common in males. It had a higher incidence in SCLC. Peripheral neuropathy was the most common PNS associated with SCLC, followed by Lambert‐Eaton syndrome. Peripheral neuropathy and limbic encephalitis were the most common PNS associated with NSCLC. Anti‐Hu is the most common antibodies both in SCLC and NSCLC. Tumor markers do not have significant difference between different pathological types.

1 March 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
SQShan Qiao
Shan Qiao
HLHaiyun Li
Haiyun Li
CCCaisan Cui
Caisan Cui
CZChong Zhang
Chong Zhang
AWAihua Wang
Aihua Wang
SZShanchao Zhang
Shanchao Zhang
Purpose: CSF inflammation in subtypes of antibody-defined autoimmune encephalitis (AE) ranges in intensity from moderate to severe. In a retrospective, cross-sectional study, we characterized CSF findings in Chinese patients with anti-N-methyl-D-aspartate receptor encephalitis (NMDAR-E), anti-leucine-rich glioma-inactivated 1 encephalitis (LGI1-E), and anti-gamma aminobutyric acid-B receptor encephalitis (GABABR-E). Patients and Methods: The AE cases, including 102 NMDAR-E, 68 LGI1-E and 15 GABABR-E, were included. CSF inflammatory parameters consisted primarily of CSF leukocytes, oligoclonal bands (OCBs), and CSF/serum albumin ratios (QAlb). Ten serum cytokines were evaluated in order to classify AE subtypes. Results: 88% of NMDAR-E, 80% of GABABR-E, and 51% of LGI1-E patients had aberrant CSF features. In NMDAR-E, the CSF leukocyte count, CSF protein concentration, and age-adjusted QAlb were significantly higher than in LGI1-E, but did not differ from GABABR-E. Blood-CSF barrier dysfunction was less common in NMDAR-E patients with > 40 years old. On admission, inflammatory CSF response was more prevalent in NMDAR-E patients with a higher CASE score. With age < 60 years, CSF inflammatory changes were less frequent in LGI1-E patients, but more common in GABABR-E patients. MCP-1, IL-10, IL-1β, and IL-4 were potential classifiers for NMDAR-E, LGI1-E, and GABABR-E, and correlated substantially with CSF leukocyte count and QAlb. Conclusion: Subtype-specific patterns are formed by the various inflammatory CSF parameters in NMDAR-E, LGI1-E, and GABABR-E, and their correlation with disease severity, age, and disease duration. CSF inflammatory characteristics associated with MCP-1, IL-10, IL-1β, and IL-4 may be potential immunopathogeneses targeting markers for these AE subtypes.

18 August 2025 in Biomedical Signal Processing and Control
Verified
Journal Article
Closed access
XBXiaochan Bi
Xiaochan Bi
JLJianxin Liu
Jianxin Liu
FMFanzun Meng
Fanzun Meng
HLHaiyun Li
Haiyun Li
JMJun Ma
Jun Ma
WJWenjing Jiang
Wenjing Jiang

18 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JGJinyang Gao
Jinyang Gao
XBXiaochan Bi
Xiaochan Bi
WJWenjing Jiang
Wenjing Jiang
YWYanqing Wang
Yanqing Wang
Alzheimer’s Disease (AD) is the leading cause of dementia globally, significantly impacting health and socio-economic sectors. Our study aims to elucidate the molecular basis of AD using an integrated multi-omics approach. We utilized a combination of genomics, transcriptomics, and proteomics data from multiple tissues (blood, cerebrospinal fluid and brain). Summary-data-based Mendelian Randomization (SMR), colocalization analysis and Heterogeneity in Dependent Instruments (HEIDI) analyses were conducted to establish causality between genetic variants and AD risk. Our results identified causal relationships across multiple omics layers, with significant findings for the Angiotensin-converting enzyme (ACE) and CD33 molecule (CD33) genes. For ACE, our analyses across methylation, expression, and protein levels revealed an overall odds ratio (OR) indicating a protective effect against AD. Specifically, increased methylation at cg04199256 and cg21657705 was associated with higher ACE expression. CD33 demonstrated an increased risk of AD (OR = 1.17, 95% CI: 1.09–1.25).Both genes showed strong colocalization signals, with ACE and CD33 having posterior probability values (PP.H4) of 0.99 and 0.95, respectively. The proteins TMEM106B (PP.H4 = 0.96), SIRPA (PP.H4 = 0.92), CTSH (PP.H4 = 0.77), and CLN5 (PP.H4 = 0.92) also showed strong colocalization evidence. At the protein level, genetically predicted higher levels of TMEM106B (OR 1.44, 95% CI 1.24–1.68), SIRPA (OR 1.03, 95% CI 1.02–1.04) and CTSH (OR 1.04, 95% CI 1.03–1.06) was associated with an increased risk of AD; genetically predicted higher level of CLN5 were inversely associated with AD risk (OR 0.69, 95% CI 0.58–0.83). By identifying multiple candidate targets and regulatory axes, our findings offer a valuable resource for prioritizing genes for functional validation and advancing future therapeutic development.